Natural Products and Hepatitis C Virus

  • Karin Séron
  • Marie-Emmanuelle Sahuc
  • Yves Rouillé
Part of the Sustainable Development and Biodiversity book series (SDEB, volume 19)


Hepatitis C is a major health problem worldwide. For a long time, it has not been possible to grow in cell culture the virus responsible for this disease. This impeded the development of efficient antiviral treatments. In the past decade, the establishment of a hepatitis C virus (HCV) cell culture model led to numerous studies aiming at finding chemical compounds with anti-HCV activity. A number of natural compounds were isolated and identified from plants, which inhibit various steps of the HCV life cycle. A review of the current knowledge on plant-derived natural compounds with anti-HCV activities is presented in this chapter.


Hepatitis C virus Antiviral agent Plant extract Traditional medicine Bioactive molecule 



We thank Jean Dubuisson for his support and for useful discussions and Sophana Ung for preparing the illustrations. HCV research conducted by the authors is supported by “Université de Lille” and “Centre National de la Recherche Scientifique” (CNRS) via a PEPS project.


  1. Adianti M, Aoki C, Komoto M, Deng L, Shoji I, Wahyuni TS, Lusida MI, Soetjipto, Fuchino H, Kawahara N, Hotta H (2014) Anti-hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza species. Microbiol Immunol 58:180–187Google Scholar
  2. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl R-T, Pawlotsky J-M (2010) Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 138:1112–1122Google Scholar
  3. Ahmed-Belkacem A, Guichou J-F, Brillet R, Ahnou N, Hernandez E, Pallier C, Pawlotsky J-M (2014) Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention. Nucleic Acids Res 42:9399–9409Google Scholar
  4. Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E (2014) Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 63:1137–1149Google Scholar
  5. Aoki C, Hartati SRI, Santi MEIRIA, Firdaus R, Hanafi M, Kardono LBS, Shimizu Y, Sudarmono P, Hotta HAK (2014) Isolation and identification of substances with anti-hepatitis C virus activities from Kalanchoe pinnata. Int J Pharm Pharm Sci 6:211–215Google Scholar
  6. Ashfaq UA, Jalil A, Ul Qamar MT (2015) Antiviral phytochemicals identification from Azadirachta indica leaves against HCV NS3 protease: an in silico approach. Nat Prod Res:1–4Google Scholar
  7. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S (2011a) Inhibition of HCV 3a core gene through Silymarin and its fractions. Virol J 8:153PubMedPubMedCentralCrossRefGoogle Scholar
  8. Ashfaq UA, Masoud MS, Nawaz Z, Riazuddin S (2011b) Glycyrrhizin as antiviral agent against Hepatitis C Virus. J Transl Med 9:112PubMedPubMedCentralCrossRefGoogle Scholar
  9. Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R (2012) Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat 19:e81–e88PubMedCrossRefGoogle Scholar
  10. Balunas MJ, Kinghorn AD (2005) Drug discovery from medicinal plants. Life Sci 78:431–441PubMedCrossRefGoogle Scholar
  11. Bartenschlager R, Penin F, Lohmann V, André P (2011) Assembly of infectious hepatitis C virus particles. Trends Microbiol 19:95–103PubMedCrossRefGoogle Scholar
  12. Bartosch B, Dubuisson J, Cosset F-L (2003) Infectious Hepatitis C Virus Pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med 197:633–642PubMedPubMedCentralCrossRefGoogle Scholar
  13. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P (2010) Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol 54:591–592PubMedCrossRefGoogle Scholar
  14. Berdichevsky Y, Zemel R, Bachmatov L, Abramovich A, Koren R, Sathiyamoorthy P, Golan-Goldhirsh A, Tur-Kaspa R, Benhar I (2003) A novel high throughput screening assay for HCV NS3 serine protease inhibitors. J Virol Methods 107:245–255PubMedCrossRefGoogle Scholar
  15. Bhat R, Adam AT, Lee JJ, Deloison G, Rouillé Y, Séron K, Rotella DP (2014) Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors. Bioorg Med Chem Lett 24:4162–4165PubMedCrossRefGoogle Scholar
  16. Blaising J, Lévy PL, Gondeau C, Phelip C, Varbanov M, Teissier E, Ruggiero F, Polyak SJ, Oberlies NH, Ivanovic T, Boulant S, Pécheur EI (2013) Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol 15:1866–1882PubMedGoogle Scholar
  17. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouillé Y (2006) Hepatitis C Virus entry depends on Clathrin-mediated endocytosis. J Virol 80:6964–6972PubMedPubMedCentralCrossRefGoogle Scholar
  18. Blazquez AG, Fernandez-Dolon M, Sanchez-Vicente L, Maestre AD, Gomez-San Miguel AB, Alvarez M, Serrano MA, Jansen H, Efferth T, Marin JJG, Romero MR (2013) Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorg Med Chem 21:4432–4441PubMedCrossRefGoogle Scholar
  19. Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in Cell culture. Science 290:1972–1974PubMedCrossRefGoogle Scholar
  20. Blight KJ, McKeating JA, Rice CM (2002) Highly permissive cell lines for subgenomic and genomic Hepatitis C Virus RNA replication. J Virol 76:13001–13014PubMedPubMedCentralCrossRefGoogle Scholar
  21. Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouillé Y, Séron K (2012) (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatol Baltim Md 55:720–729CrossRefGoogle Scholar
  22. Calland N, Sahuc M-E, Belouzard S, Pène V, Bonnafous P, Mesalam AA, Deloison G, Descamps V, Sahpaz S, Wychowski C, Lambert O, Brodin P, Duverlie G, Meuleman P, Rosenberg AR, Dubuisson J, Rouillé Y, Séron K (2015) Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. J VirolGoogle Scholar
  23. Cao M-M, Zhang Y, Li X-H, Peng Z-G, Jiang J-D, Gu Y-C, Di Y-T, Li X-N, Chen D-Z, Xia C-F, He H-P, Li S-L, Hao X-J (2014) Cyclohexane-fused octahydroquinolizine alkaloids from Myrioneuron faberi with activity against Hepatitis C Virus. J Org Chem 79:7945–7950PubMedCrossRefGoogle Scholar
  24. Chao C-H, Cheng J-C, Shen D-Y, Wu T-S (2014) Anti-hepatitis C virus dinorditerpenes from the roots of Flueggea virosa. J Nat Prod 77:22–28PubMedCrossRefGoogle Scholar
  25. Chen C, Qiu H, Gong J, Liu Q, Xiao H, Chen XW, Sun BL, Yang RG (2012a) (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Arch Virol 157:1301–1312PubMedCrossRefGoogle Scholar
  26. Chen M-H, Lee M-Y, Chuang J-J, Li Y-Z, Ning S-T, Chen J-C, Liu Y-W (2012b) Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT. Int J Mol Med 30:1021–1028PubMedPubMedCentralCrossRefGoogle Scholar
  27. Chen W-C, Wang S-Y, Chiu C-C, Tseng C-K, Lin C-K, Wang H-C, Lee J-C (2013) Lucidone Suppresses Hepatitis C Virus Replication by Nrf2-Mediated Heme Oxygenase-1 Induction. Antimicrob Agents Chemother 57:1180–1191PubMedPubMedCentralCrossRefGoogle Scholar
  28. Chung C-Y, Liu C-H, Burnouf T, Wang G-H, Chang S-P, Jassey A, Tai C-J, Tai C-J, Huang C-J, Richardson CD, Yen M-H, Lin C-C, Lin L-T (2016) Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. Antiviral Res 130:58–68PubMedCrossRefGoogle Scholar
  29. Ciesek S, Von Hahn T, Colpitts CC, Schang LM, Friesland M, Rg Steinmann J, Manns MP, Ott M, Wedemeyer H, Meuleman P, Pietschmann T, Steinmann E (2011) The Green Tea polyphenol, epigallocatechin-3-Gallate, inhibits Hepatitis C Virus entry. Hepatology 54:1947–1955PubMedCrossRefGoogle Scholar
  30. Colpitts CC, Schang LM (2014) A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans. J Virol 88:7806–7817PubMedPubMedCentralCrossRefGoogle Scholar
  31. Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol, 100th volume special section. Perspect Ethnopharmacol 100:72–79Google Scholar
  32. Duan D, Li Z, Luo H, Zhang W, Chen L, Xu X (2004) Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 14:6041–6044PubMedCrossRefGoogle Scholar
  33. Dubuisson J, Helle F, Cocquerel L (2008) Early steps of the hepatitis C virus life cycle. Cell Microbiol 10:821–827PubMedCrossRefGoogle Scholar
  34. Dubuisson J, Rice CM (1996) Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. J Virol 70:778–786PubMedPubMedCentralGoogle Scholar
  35. Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K (2002) Expression of Hepatitis C Virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76:5974–5984PubMedPubMedCentralCrossRefGoogle Scholar
  36. Elsebai MF, Koutsoudakis G, Saludes V, Pérez-Vilaró G, Turpeinen A, Mattila S, Pirttilä AM, Fontaine-Vive F, Mehiri M, Meyerhans A, Diez J (2016) Pan-genotypic Hepatitis C Virus inhibition by natural products derived from the Wild Egyptian Artichoke. J Virol 90:1918–1930PubMedPubMedCentralCrossRefGoogle Scholar
  37. Esser-Nobis K, Romero-Brey I. es, Ganten TM, Gouttenoire J erome, Harak C, Klein R, Schemmer P, Binder M, Schnitzler P, Moradpour D, Bartenschlager R, Polyak SJ, Stremmel W, Penin F, Eisenbach C, Lohmann V (2013) Analysis of Hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatol Baltim Md 53:953–963Google Scholar
  38. Eurich D, Bahra M, Berg T, Boas-Knoop S, Biermer M, Neuhaus R, Neuhaus P, Neumann U (2011) Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp Clin Transplant Off J Middle East Soc Organ Transplant 9:1–6Google Scholar
  39. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. NatureGoogle Scholar
  40. Ezzikouri S, Nishimura T, Kohara M, Benjelloun S, Kino Y, Inoue K, Matsumori A, Tsukiyama-Kohara K (2015) Inhibitory effects of Pycnogenol® on hepatitis C virus replication. Antiviral Res 113:93–102PubMedCrossRefGoogle Scholar
  41. Falson P, Bartosch B, Alsaleh K, Tews BA, Loquet A, Ciczora Y, Riva L, Montigny C, Montpellier C, Duverlie G, Pécheur E-I, le Maire M, Cosset F-L, Dubuisson J, Penin F (2015) Hepatitis C Virus envelope glycoprotein E1 forms trimers at the surface of the virion. J Virol 89:10333–10346PubMedPubMedCentralCrossRefGoogle Scholar
  42. Fatima K, Mathew S, Suhail M, Ali A, Damanhouri G, Azhar E, Qadri I (2014) Docking studies of Pakistani HCV NS3 helicase: a possible antiviral drug target. PLoS ONE 9:e106339PubMedPubMedCentralCrossRefGoogle Scholar
  43. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P (2008) Silibinin is a potent antiviral agent in patients with chronic Hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135:1561–1567PubMedCrossRefGoogle Scholar
  44. Ferraris P, Blanchard E, Roingeard P (2010) Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes. J Gen Virol 91:2230–2237PubMedCrossRefGoogle Scholar
  45. Fukazawa H, Suzuki T, Wakita T, Murakami Y (2012) A cell-based, microplate colorimetric screen identifies 7,8-benzoflavone and green tea gallate catechins as inhibitors of the Hepatitis C Virus. Biol Pharm Bull 35:1320–1327PubMedCrossRefGoogle Scholar
  46. Galani BRT, Sahuc M-E, Njayou FN, Deloison G, Mkounga P, Feudjou WF, Brodin P, Rouillé Y, Nkengfack AE, Moundipa PF, Séron K (2015) Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. Front Microbiol 6:488PubMedPubMedCentralCrossRefGoogle Scholar
  47. Galani BRT, Sahuc M-E, Sass G, Njayou FN, Loscher C, Mkounga P, Deloison G, Brodin P, Rouillé Y, Tiegs G, Séron K, Moundipa PF (2016) Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. Arch Virol 161:1169–1181PubMedCrossRefGoogle Scholar
  48. Galani BRT, Sass G, Njayou NF, Mkounga P, Tiegs G, Moundipa PF (2014) Anti-hepatitis C virus activity of crude extract and fractions of Entada africana in genotype 1b replicon systems. Am J Chin Med 42:853–868CrossRefGoogle Scholar
  49. Gentzsch J, Hinkelmann B, Kaderali L, Irschik H, Jansen R, Sasse F, Frank R, Pietschmann T (2011) Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Res 89:136–148PubMedCrossRefGoogle Scholar
  50. Goldwasser J, Cohen PY, Lin W, Kitsberg D, Polyak SJ, Chung RT, Yarmush ML (2011) Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol 55:963–971PubMedPubMedCentralCrossRefGoogle Scholar
  51. Gonzalez O, Fontanes V, Raychaudhuri S, Loo R, Loo J, Arumugaswami V, Sun R, Dasgupta A, French SW (2009) The heat shock protein inhibitor quercetin attenuates hepatitis C virus production. Hepatology 50:1756–1764PubMedCrossRefGoogle Scholar
  52. Graham CS, Swan T (2015) A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res 119:89–96PubMedCrossRefGoogle Scholar
  53. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS (2012) Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J Hepatol 56:1019–1024PubMedPubMedCentralCrossRefGoogle Scholar
  54. Haid S, Novodomská A, Gentzsch J, Grethe C, Geuenich S, Bankwitz D, Chhatwal P, Jannack B, Hennebelle T, Bailleul F, Keppler OT, Poenisch M, Bartenschlager R, Hernandez C, Lemasson M, Rosenberg AR, Wong-Staal F, Davioud-Charvet E, Pietschmann T (2012) A plant-derived flavonoid inhibits entry of All HCV genotypes into human hepatocytes. Gastroenterology 143:213–222PubMedCrossRefGoogle Scholar
  55. Hegde VR, Pu H, Patel M, Das PR, Butkiewicz N, Arreaza G, Gullo VP, Chan TM (2003) Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 13:2925–2928PubMedCrossRefGoogle Scholar
  56. Hsu W-C, Chang S-P, Lin L-C, Li C-L, Richardson CD, Lin C-C, Lin L-T (2015) Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. Antiviral Res 118:139–147PubMedCrossRefGoogle Scholar
  57. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J (2007) Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci 104:5848–5853PubMedPubMedCentralCrossRefGoogle Scholar
  58. Huang S-D, Zhang Y, Cao M-M, Di Y-T, Tang G-H, Peng Z-G, Jiang J-D, He H-P, Hao X-J (2013) Myriberine A, a new alkaloid with an unprecedented heteropentacyclic skeleton from Myrioneuron faberi. Org Lett 15:590–593PubMedCrossRefGoogle Scholar
  59. Hu JF, Patel R, Li B, Garo E, Hough GW, Goering MG, Yoo HD, O’Neil-Johnson M, Eldridge GR (2007) Anti-HCV bioactivity of pseudoguaianolides from Parthenium hispitum. J Nat Prod 70:604–607PubMedCrossRefGoogle Scholar
  60. Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno K (2000) Inhibitory effects of sudanese medicinal plant extracts on hepatitis C virus (HCV) protease. Phytother Res PTR 14:510–516PubMedCrossRefGoogle Scholar
  61. Jardim ACG, Igloi Z, Shimizu JF, Santos VAFFM, Felippe LG, Mazzeu BF, Amako Y, Furlan M, Harris M, Rahal P (2015) Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Antiviral Res 115:39–47PubMedPubMedCentralCrossRefGoogle Scholar
  62. Javed T, Ashfaq UA, Riaz S, Rehman S, Riazuddin S (2011) In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus. Virol J 8:26PubMedPubMedCentralCrossRefGoogle Scholar
  63. Kaushik-Basu N, Bopda-Waffo A, Talele TT, Basu A, Costa PRR, da Silva AJM, Sarafianos SG, Noël F (2008) Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res 36:1482–1496PubMedPubMedCentralCrossRefGoogle Scholar
  64. Khachatoorian R, Arumugaswami V, Raychaudhuri S, Yeh G, Maloney EM, Wang J, Dasgupta A, French S (2012) Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle. Virology 433:346–355PubMedPubMedCentralCrossRefGoogle Scholar
  65. Khan M, Masoud MS, Qasim M, Khan MA, Zubair M, Idrees S, Ashraf A, Ashfaq UA (2013a) Molecular screening of phytochemicals from Amelanchier Alnifolia against HCV NS3 protease/ helicase using computational docking techniques. Bioinformation 9:978–982PubMedPubMedCentralCrossRefGoogle Scholar
  66. Khan M, Qasim M, Ashfaq UA, Idrees S, Shah M (2013b) Computer aided screening of Accacia nilotica phytochemicals against HCV NS3/ 4a. Bioinformation 9:710–714PubMedPubMedCentralCrossRefGoogle Scholar
  67. Kim J-W, Park SJ, Lim JH, Yang JW, Shin JC, Kim E-J, Suh JW, Hwang SB, Kim JW (2013) Triterpenoids from Platycodon grandiflorum Inhibit Hepatitis C Virus Replication. Evid Based Complement Alternat MedGoogle Scholar
  68. Kim K, Kim KH, Kim HY, Cho HK, Sakamoto N, Cheong J (2010) Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway. FEBS Lett 584:707–712PubMedCrossRefGoogle Scholar
  69. Kim T-W, Lim J-H, Song I-B, Park S-J, Yang J-W, Shin JC, Suh J-W, Son H-Y, Cho E-S, Kim M-S, Lee S-W, Kim J-W, Yun H-I (2012) Hepatoprotective and anti-Hepatitis C viral activity of Platycodon grandiflorum extract on carbon tetrachloride-induced acute hepatic injury in mice. J Nutr Sci Vitaminol (Tokyo) 58:187–194CrossRefGoogle Scholar
  70. Kong L, Li S, Han X, Xiang Z, Fang X, Li B, Wang W, Zhong H, Gao J, Ye L (2007) Inhibition of HCV RNA-dependent RNA polymerase activity by aqueous extract from Fructus Ligustri Lucidi. Virus Res 128:9–17PubMedCrossRefGoogle Scholar
  71. Kong L, Li S, Liao Q, Zhang Y, Sun R, Zhu X, Zhang Q, Wang J, Wu X, Fang X, Zhu Y (2013) Oleanolic acid and ursolic acid: novel hepatitis C virus antivirals that inhibit NS5B activity. Antiviral Res 98:44–53PubMedCrossRefGoogle Scholar
  72. Lan K-H, Wang Y-W, Lee W-P, Lan K-L, Tseng S-H, Hung L-R, Yen S-H, Lin H-C, Lee S-D (2012) Multiple effects of Honokiol on the life cycle of hepatitis C virus. Liver Int Off J Int Assoc Study Liver 32:989–997CrossRefGoogle Scholar
  73. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107–115PubMedCrossRefGoogle Scholar
  74. Lee H, Yum J, Rho Y, Oh S, Choi H, Chang H, Choi D, Leem M-J, Choi E, Ryu J, Hwang S (2007) Inhibition of HCV replicon cell growth by 2-Arylbenzofuran derivatives isolated from Mori Cortex Radicis. Planta Med 73:1481–1485PubMedCrossRefGoogle Scholar
  75. Lee JC, Chen WC, Wu SF, Tseng CK, Chiou CY, Chang FR, Hsu SH, Wu YC (2011a) Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2. Antiviral Res 89:35–42PubMedCrossRefGoogle Scholar
  76. Lee JC, Tseng CK, Wu SF, Chang FR, Chiu CC, Wu YC (2011b) San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression. J Viral Hepat 18:e115–e324CrossRefGoogle Scholar
  77. Lee S, Yoon KD, Lee M, Cho Y, Choi G, Jang H, Kim B, Jung D-H, Oh J-G, Kim G-W, Oh J-W, Jeong Y-J, Kwon HJ, Bae SK, Min D-H, Windisch MP, Heo T-H, Lee C (2016) Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. Br J Pharmacol 173:191–211PubMedCrossRefGoogle Scholar
  78. Levrero M (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25:3834–3847PubMedCrossRefGoogle Scholar
  79. Liang TJ, Ghany MG (2013) Current and Future Therapies for Hepatitis C Virus Infection. N Engl J Med 368:1907–1917PubMedPubMedCentralCrossRefGoogle Scholar
  80. Lindenbach BD, Rice CM (2013) The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11:688–700PubMedPubMedCentralCrossRefGoogle Scholar
  81. Lindenbach BD, Thiel H-J, Rice CM (2007) Flaviviridae: the viruses and their replication. In: David M (ed) Fields virology, 5th edn. Knipe, Peter, M. Howley, pp 1101–1152Google Scholar
  82. Lin L-T, Chung C-Y, Hsu W-C, Chang S-P, Hung T-C, Shields J, Russell RS, Lin C-C, Li C-F, Yen M-H, Tyrrell DLJ, Lin C-C, Richardson CD (2015) Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. J Hepatol 62:541–548PubMedCrossRefGoogle Scholar
  83. Lin YT, Wu YH, Tseng CK, Lin CK, Chen WC, Hsu YC, Lee JC (2013) Green Tea phenolic epicatechins inhibit Hepatitis C Virus replication via Cycloxygenase-2 and attenuate virus-induced inflammation. PLoS ONE 8:1–10Google Scholar
  84. Li S, Kodama EN, Inoue Y, Tani H, Matsuura Y, Zhang J, Tanaka T, Hattori T (2010) Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication. Antivir Chem Chemother 20:239–248PubMedGoogle Scholar
  85. Liu MM, Zhou L, He PL, Zhang YN, Zhou JY, Shen Q, Chen XW, Zuo JP, Li W, Ye DY (2012) Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy. Eur J Med Chem 52:33–43PubMedCrossRefGoogle Scholar
  86. Li Y, Yu S, Liu D, Proksch P, Lin W (2012) Inhibitory effects of polyphenols toward HCV from the mangrove plant Excoecaria agallocha L. Bioorg Med Chem Lett 22:1099–1102PubMedCrossRefGoogle Scholar
  87. Lohmann V, Körner F, Koch J-O, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic Hepatitis C Virus RNAs in a hepatoma cell line. Science 285:110–113PubMedCrossRefGoogle Scholar
  88. Lulu SS, Thabitha A, Vino S, Priya AM, Rout M (2015) Naringenin and quercetin - potential anti-HCV agents for NS2 protease targets. Nat Prod Res:1–5Google Scholar
  89. Lu NT, Crespi CM, Liu NM, Vu JQ, Ahmadieh Y, Wu S, Lin S, McClune A, Durazo F, Saab S, Han S, Neiman DC, Beaven S, French SW (2015) A Phase I dose escalation study demonstrates quercetin safety and explores potential for bioflavonoid antivirals in patients with chronic Hepatitis C. Phytother Res PTRGoogle Scholar
  90. Ma CM, Nakamura N, Miyashiro H, Hattori M, Shimotohno K (1999) Inhibitory effects of constituents from Cynomorium songaricum and related triterpene derivatives on HIV-1 protease. Chem. Pharm. Bull. (Tokyo) 47:141–145CrossRefGoogle Scholar
  91. Ma CM, Wei Y, Wang ZG, Hattori M (2009) Triterpenes from Cynomorium songaricium—Analysis of HCV protease inhibitory activity, quantification, and content change under the influence of heating. J Nat Med 63:9–14PubMedCrossRefGoogle Scholar
  92. Ma JN, Bolraa S, Ji M, He QQ, Ma CM (2015) Quantification and antioxidant and anti-HCV activities of the constituents from the inflorescences of Scabiosa comosa and S. tschilliensis. Nat Prod Res:1–5Google Scholar
  93. Manvar D, Mishra M, Kumar S, Pandey VN (2012) Identification and evaluation of anti hepatitis C virus phytochemicals from Eclipta alba. J Ethnopharmacol 144:545–554PubMedPubMedCentralCrossRefGoogle Scholar
  94. Mathew S, Fatima K, Fatmi MQ, Archunan G, Ilyas M, Begum N, Azhar E, Damanhouri G, Qadri I (2015) Computational docking study of p7 Ion channel from HCV Genotype 3 and Genotype 4 and its interaction with natural compounds. PLoS ONE 10:e0126510PubMedPubMedCentralCrossRefGoogle Scholar
  95. Matsumoto Y, Matsuura T, Aoyagi H, Matsuda M, Hmwe S, Date T, Watanabe N, Watashi K, Suzuki R, Ichinose S, Wake K, Suzuki T, Miyamura T, Wakita T, Aizaki H (2013) Antiviral activity of glycyrrhizin against hepatitis C virus in vitro. PLoS ONE 8:e68992PubMedPubMedCentralCrossRefGoogle Scholar
  96. McLauchlan J, Lemberg MK, Hope G, Martoglio B (2002) Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 21:3980–3988PubMedPubMedCentralCrossRefGoogle Scholar
  97. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77–87PubMedCrossRefGoogle Scholar
  98. Meuleman P, Leroux-Roels G (2008) The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 80:231–238PubMedCrossRefGoogle Scholar
  99. Mirza MU, Ghori N, Ikram N, Adil AR, Manzoor S (2015) Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors. Drug Des Devel Ther 9:1825–1841PubMedPubMedCentralCrossRefGoogle Scholar
  100. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K (2007) The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:1089–1097PubMedCrossRefGoogle Scholar
  101. Moradpour D, Penin F (2013) Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 369:113–142PubMedGoogle Scholar
  102. Nahmias Y, Goldwasser J, Casali M, Van Poll D, Wakita T, Chung RT, Yarmush ML (2008) Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47:1437–1445PubMedPubMedCentralCrossRefGoogle Scholar
  103. Neuman U, Biermer M, Eurich D, Neuhaus P, Berg T (2010) Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 52:951–952CrossRefGoogle Scholar
  104. Nichols DB, Leão R. a C, Basu A, Chudayeu M, de Moraes PDF, Talele TT, Costa PRR, Kaushik-Basu N (2013) Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors. Chem Biol Drug Des 81:607–614Google Scholar
  105. Noreen S, Hussain I, Tariq MI, Ijaz B, Iqbal S, Qamar-ul-Zaman Ashfaq UA, Husnain T (2015) Portulaca oleracea L. as a Prospective Candidate Inhibitor of Hepatitis C Virus NS3 Serine Protease. Viral Immunol 28:282–289Google Scholar
  106. Obeid S, Alen J, Nguyen VH, Pham VC, Meuleman P, Pannecouque C, Le TN, Neyts J, Dehaen W, Paeshuyse J (2013) Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication. PLoS ONE 8:e81783PubMedPubMedCentralCrossRefGoogle Scholar
  107. Ohno M, Shibata C, Kishikawa T, Yoshikawa T, Takata A, Kojima K, Akanuma M, Kang YJ, Yoshida H, Otsuka M, Koike K (2013) The flavonoid apigenin improves glucose tolerance through inhibition of microRNA maturation in miRNA103 transgenic mice. Sci Rep 3:2553PubMedPubMedCentralCrossRefGoogle Scholar
  108. Paeshuyse J, Coelmont L, Vliegen I, Van hemel J, Vandenkerckhove J, Peys E, Sas B, De Clercq E, Neyts J (2006) Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin. Biochem Biophys Res Commun 348:139–144Google Scholar
  109. Paul D, Bartenschlager R (2015) Flaviviridae replication organelles: oh, what a tangled web we weave. Annu Rev Virol 2:289–310PubMedCrossRefGoogle Scholar
  110. Pawlotsky J (2014) New Hepatitis C Therapies: the toolbox, strategies, and challenges. Gastroenterology 146:1176–1192PubMedCrossRefGoogle Scholar
  111. Pawlotsky J-M (2016) Hepatitis C Virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151:70–86Google Scholar
  112. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282:938–941PubMedCrossRefGoogle Scholar
  113. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882–886PubMedPubMedCentralCrossRefGoogle Scholar
  114. Podevin P, Carpentier A, Pène V, Aoudjehane L, Carrière M, Zaïdi S, Hernandez C, Calle V, Méritet J, Scatton O, Dreux M, Cosset F, Wakita T, Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y (2010) Production of infectious Hepatitis C Virus in primary cultures of human adult hepatocytes. Gastroenterology 139(1355–1364):e6Google Scholar
  115. Polyak SJ, Oberlies NH, Pécheur E-I, Dahari H, Ferenci P, Pawlotsky1 J-M (2013) Silymarin for hepatitis C virus infection. Antivir Ther 18, 141–147Google Scholar
  116. Popescu C-I, Riva L, Vlaicu O, Farhat R, Rouillé Y, Dubuisson J (2014) Hepatitis C Virus life cycle and lipid metabolism. Biology 3:892–921PubMedPubMedCentralCrossRefGoogle Scholar
  117. Qian X-J, Zhang X-L, Zhao P, Jin Y-S, Chen H-S, Xu Q-Q, Ren H, Zhu S-Y, Tang H-L, Zhu Y-Z, Qi Z-T (2016) A Schisandra-derived compound schizandronic acid inhibits entry of Pan-HCV genotypes into human hepatocytes. Sci Rep 6:27268PubMedPubMedCentralCrossRefGoogle Scholar
  118. Ramasamy K, Agarwal R (2008) Multitargeted therapy of cancer by silymarin. Cancer Lett Natural Products Special Issue 269:352–362Google Scholar
  119. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM (2007) Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci 104:12884–12889PubMedPubMedCentralCrossRefGoogle Scholar
  120. Rashed K, Sahuc M-E, Deloison G, Calland N, Brodin P, Rouillé Y, Séron K (2014) Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro. J Funct Foods 11:185–191CrossRefGoogle Scholar
  121. Ratnoglik SL, Aoki C, Sudarmono P, Komoto M, Deng L, Shoji I, Fuchino H, Kawahara N, Hotta H (2014) Antiviral activity of extracts from Morinda citrifolia leaves and chlorophyll catabolites, pheophorbide a and pyropheophorbide a, against hepatitis C virus. Microbiol Immunol 58:188–194PubMedCrossRefGoogle Scholar
  122. Ravikumar YS, Ray U, Nandhitha M, Perween A, Raja Naika H, Khanna N, Das S (2011) Inhibition of hepatitis C virus replication by herbal extract: Phyllanthus amarus as potent natural source. Virus Res 158:89–97PubMedCrossRefGoogle Scholar
  123. Reddy BU, Mullick R, Kumar A, Sudha G, Srinivasan N, Das S (2014) Small molecule inhibitors of HCV replication from Pomegranate. Sci Rep 4:5411PubMedPubMedCentralCrossRefGoogle Scholar
  124. Rehman S, Ashfaq U a, Riaz S, Javed T, Riazuddin S (2011) Antiviral activity of Acacia nilotica against Hepatitis C Virus in liver infected cells. Virol J 8:220Google Scholar
  125. Rivero-Buceto E, Carrero P, Doyaguez EG, Madrona A, Quesada E, Camarasa MJ, Perez-Perez MJ, Leyssen P, Paeshuyse J, Balzarini J, Neyts J, San-f A (2015) Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti- HCV inhibitors. Eur J Med Chem 92:656–671CrossRefGoogle Scholar
  126. Romero-Brey I, Merz A, Chiramel A, Lee J-Y, Chlanda P, Haselman U, Santarella-Mellwig R, Habermann A, Hoppe S, Kallis S, Walther P, Antony C, Krijnse-Locker J, Bartenschlager R (2012) Three-dimensional architecture and biogenesis of membrane structures associated with Hepatitis C Virus replication. PLoS Pathog 8:e1003056PubMedPubMedCentralCrossRefGoogle Scholar
  127. Salah El Dine R, Abdel Monem AR, El-Halawany AM, Hattori M, Abdel-Sattar E (2011) HCV-NS3/4A protease inhibitory iridoid glucosides and dimeric foliamenthoic acid derivatives from Anarrhinum orientale. J Nat Prod 74:943–948PubMedCrossRefGoogle Scholar
  128. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21:5017–5025PubMedPubMedCentralCrossRefGoogle Scholar
  129. Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, Nishimura-Sakurai Y, Chen C, Suda G, Mishima K, Onuki Y, Yamamoto M, Maekawa S, Enomoto N, Kanai T, Tsuchiya K, Watanabe M (2009) Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replication. Hepatol Res 39:60–69PubMedCrossRefGoogle Scholar
  130. Sharaf M, El-Deeb N, El-Adawi H (2012) The potentiality of grape seed extract as a novel anti-hepatitis C virus agent. J Med Sci 12:107–113CrossRefGoogle Scholar
  131. Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, Tanaka T, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Shindo H, Maekawa S, Enomoto N, Tsubuki M, Moriishi K (2013) Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus. PLoS ONE 8:1–11CrossRefGoogle Scholar
  132. Shibata C, Ohno M, Otsuka M, Kishikawa T, Goto K, Muroyama R, Kato N, Yoshikawa T, Takata A, Koike K (2014) The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology 462–463:42–48PubMedCrossRefGoogle Scholar
  133. Suzuki M, Sasaki K, Yoshizaki F, Fujisawa M, Oguchi K, Cyong J-C (2005) Anti-hepatitis C virus effect of citrus unshiu peel and its active ingredient nobiletin. Am J Chin Med 33:87–94PubMedCrossRefGoogle Scholar
  134. Takeshita M, Ishida Y, Akamatsu E, Ohmori Y, Sudoh M, Uto H, Tsubouchi H, Kataoka H (2009) Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem 284:21165–21176PubMedPubMedCentralCrossRefGoogle Scholar
  135. Tamura S, Yang GM, Yasueda N, Matsuura Y, Komoda Y, Murakami N (2010) Tellimagrandin I, HCV invasion inhibitor from Rosae Rugosae Flos. Bioorg Med Chem Lett 20:1598–1600PubMedCrossRefGoogle Scholar
  136. Tarr AW, Khera T, Hueging K, Sheldon J, Steinmann E, Pietschmann T, Brown RJP (2015) Genetic diversity underlying the envelope Glycoproteins of Hepatitis C Virus: structural and functional consequences and the implications for vaccine design. Viruses 7:3995–4046PubMedPubMedCentralCrossRefGoogle Scholar
  137. Tietjen I, Ntie-Kang F, Mwimanzi P, Onguéné PA, Scull M a, Idowu TO, Ogundaini AO, Meva’a LM, Abegaz BM, Rice CM, Andrae-Marobela K, Brockman M a, Brumme ZL, Fedida D (2015) Screening of the Pan-African natural product library identifies Ixoratannin A-2 and Boldine as novel HIV-1 inhibitors. PLoS ONE 10:e0121099Google Scholar
  138. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P, McKeating JA (2008) Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47:17–24PubMedCrossRefGoogle Scholar
  139. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J (2010) Characterization of the envelope glycoproteins associated with infectious Hepatitis C Virus. J Virol 84:10159–10168PubMedPubMedCentralCrossRefGoogle Scholar
  140. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ (2011) Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS ONE 6:e16464PubMedPubMedCentralCrossRefGoogle Scholar
  141. Wagoner J, Negash A, Kane OJ, Martinez LE, Pécheur E, Graf TN, Oberlies NH, Lohmann V, Cao F, Tavis JE, Polyak SJ (2010) Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51:1912–1921PubMedPubMedCentralCrossRefGoogle Scholar
  142. Wahyuni TS, Tumewu L, Permanasari AA, Apriani E, Adianti M, Rahman A, Widyawaruyanti A, Lusida MI, Fuad A, Fuchino H, Kawahara N, Shoji I, Deng L, Aoki C, Hotta H (2013) Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus. Virol. J. 10:259PubMedPubMedCentralCrossRefGoogle Scholar
  143. Wahyuni TS, Widyawaruyanti A, Inge M, Fuad A, Fuchino H, Kawahara N, Hayashi Y, Aoki C, Hotta H (2014) Inhibition of hepatitis C virus replication by chalepin and pseudane IX isolated from Ruta angustifolia leaves. Fitoterapia 99:276–283PubMedCrossRefGoogle Scholar
  144. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich H-G, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796PubMedPubMedCentralCrossRefGoogle Scholar
  145. Wang C, Zhang L, Cheng P, Zhang Q (2015) Inhibitory effects of Pinus massoniana bark extract on hepatitis C virus in vitro. Pharm Biol 53:451–456PubMedCrossRefGoogle Scholar
  146. Wu SF, Lin CK, Chuang YS, Chang FR, Tseng CK, Wu YC, Lee JC (2012) Anti-hepatitis C virus activity of 3-hydroxy caruilignan C from Swietenia macrophylla stems. J Viral Hepat 19:364–370PubMedCrossRefGoogle Scholar
  147. Zhang H, Rothwangl K, Mesecar AD, Sabahi A, Rong L, Fong HHS (2009) Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. J Nat Prod 72:2158–2162PubMedCrossRefGoogle Scholar
  148. Zuo G, Li Z, Chen L, Xu X (2007) Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res 76:86–92PubMedCrossRefGoogle Scholar
  149. Zuo GY, Li ZQ, Chen LR, Xu XJ (2005) In vitro anti-HCV activities of Saxifraga melanocentra and its related polyphenolic compounds. Antivir Chem Chemother 16:393–398PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Karin Séron
    • 1
  • Marie-Emmanuelle Sahuc
    • 1
  • Yves Rouillé
    • 1
  1. 1.Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL Center for Infection and Immunity of LilleLilleFrance

Personalised recommendations